Evaluating Chronic Obstructive Pulmonary Disease (COPD) Patients' Treatment Compliance and Quality of Life Via Telemedicine

NCT ID: NCT06477328

Last Updated: 2024-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2023-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Covid-19 pandemic has disrupted the follow-up and treatment processes for patients, and telemedicine has emerged as an important alternative method. Our aim was to test compare COPD Assessment Test (CAT) scores, inhaler treatment techniques and adherence between telemedicine-mediated healthcare and healthcare provided face-to-face.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Telehealth Copd

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

It is a prospective, randomized controlled, method clinical research study. Patients who were hospitalized with COPD exacerbation in the last year were included in the study and were divided into 2 groups.
Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telemedicine group

The study participants were evaluated through telemedicine visits at specific intervals after the baseline visit, with the following schedule:

* 1st visit: At day 10 post-baseline
* 2nd visit: At the end of the 1st month
* 3rd visit: At the end of the 3rd month

These visits were conducted by the principal investigator using telemedicine. Additional telemedicine visits were arranged for patients in the telemedicine group as required.

Group Type ACTIVE_COMPARATOR

Telemedicine

Intervention Type PROCEDURE

Video calls were made with the telemedicine group.

Control group

The visits for the control group, due to being conducted face-to-face in the outpatient clinic, were carried out by the routine attending physician at the clinic, who was not aware of the study. As suggested in the discharge recommendations during the baseline visit (0th visit) for the control group, they were advised to return for a follow-up visit on the 10th day and to schedule these follow-up appointments through the hospital's system. No intervention was made to facilitate the scheduling of these appointments.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telemedicine

Video calls were made with the telemedicine group.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who were diagnosed with COPD according to Global Initiative for Obstructive Lung Disease (GOLD)
* GOLD spirometric grade 3-4
* At least one hospital admission in the past year
* Acceptable score on the Mini-Mental State Examination
* Residing in Ankara
* Patient or caregiver must understand the process and be able to provide clear information
* Medical records and laboratory test results must be accessible to healthcare professionals
* Patient must have access to prescribed medications
* Comorbidities outside of the lungs are included

Exclusion Criteria

* Patients diagnosed with asthma
* Patients with lung cancer
* Patients with combined pulmonary fibrosis and emphysema
* Patients with active infections such as pneumonia or COVID-19
* Patients being followed for COPD without spirometry
* Patients with low cognitive function as determined by the Mini-Mental State Examination
* Patients who do not consent to participate in the study
* Patients lacking adequate social support
* Patients with COPD grade 1-2
* Patients with no hospital admissions in the past year
* Patients diagnosed with psychotic disorders
* Patients residing outside of Ankara
* Patients enrolled in inpatient or supervised outpatient rehabilitation programs
* Patients unable to use telemedicine devices or without a caregiver to assist
* Patients and caregivers having difficulty providing information
* Patients without internet access or video call capabilities at home
Minimum Eligible Age

40 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Etlik City Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zeynep Sena Doğan

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gazi University

Ankara, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Dogan ZS, Kokturk N. Evaluation of patients diagnosed with chronic obstructive pulmonary disease in terms of treatment compliance and quality of life after follow-up with telemedicine: a randomized controlled trial. BMC Pulm Med. 2025 Aug 26;25(1):408. doi: 10.1186/s12890-025-03854-z.

Reference Type DERIVED
PMID: 40859183 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GAZISOLMAZ01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Patient Empowerment Training for COPD Patients
NCT06201104 ENROLLING_BY_INVITATION NA